The US federal government has ordered another 1.4 million doses of Merck & Co and Ridgeback Biotherapeutics' oral antiviral molnupiravir for COVID-19, adding to an earlier agreement to
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.
The US Federal Court of Appeals has issued a temporary stay on President Joe Biden's plan for mandatory COVID-19 vaccinations for employees of businesses.
An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the early stages of infection.
Merck & Co and Ridgeback's oral antiviral molnupiravir has been approved in its first market – the UK – as a treatment for people with mild to moderate COVID-19 who are at increased ris
The US is now pressing ahead with plans to extend its COVID-19 vaccination campaign to younger children aged five and over, prompting a debate about the policy in other countries.<